Tennessee Alzheimer's Project for Aging and Cognitive Health
The Tennessee Alzheimer's Project is an observational study (meaning no new treatments are given) aiming to understand Alzheimer's disease (AD) and related memory problems better. Researchers are collecting information from people aged 60 and older, including those with normal memory, mild cognitive impairment (MCI), or Alzheimer's disease. The goal is to create a large group of participants (up to 1000 people) to help local and national researchers study AD and develop ways to detect, prevent, and treat it. The study will look at your cognitive status (memory and thinking abilities), your APOE gene type (a gene linked to AD risk), and the volume of white matter hyperintensities (changes in the brain often seen with aging). The current recruitment status is unclear.
- Study design
- This is an observational study with a planned enrollment of up to 1000 participants. It is not testing a specific drug or intervention.
- What's involved
- Participants will be followed annually. Procedures may include blood draws, questionnaires, physical exams, echocardiograms, memory tests, brain imaging, and spinal fluid collection.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' cognitive status, APOE genotype, and white matter hyperintensities volume will be measured at baseline and annually for up to three years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tennessee Alzheimer's Project
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Angela Jefferson, PhD · PRINCIPAL_INVESTIGATOR · Professor of Neurology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Cognitive statusbaseline to year 3
Change in cognitive status assessed by the Uniform Dataset according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines determined by a consensus team.
- APOE Genotypebaseline to year 3
APOE e4 allele status
- White matter hyperintensities Volumebaseline to year three
White matter lesion volume measured by FLAIR imaging modality
- Grey Matter Volumebaseline to year three
Grey matter volume measured by T1 imaging modality
- Cerebral Blood Flowbaseline to year three
Resting cerebral blood flow to brain regions measured by T3 perfusion
- Lacunar infarctsbaseline to year three
Number of lacunar infarcts measured by MRI
- Microbleedsbaseline to year three
Number of microbleeds measured by MRI
- Left ventricular ejection fractionbaseline to year three
Left ventricular ejection fraction measured by echocardiogram
- Cardiac outputbaseline to year three
Amount of blood the heart pumps from each ventricle per minute (litres per minute (L/min)), measured by echocardiogram
- Stroke volumebaseline to year three
Stroke volume measured by echocardiogram
- Heart ratebaseline to year three
Heart rate measured by echocardiogram
- Biological markers for Alzheimer's diseasebaseline to year three
Tau, amyloid, and neurodegenerative levels in cerebrospinal fluid samples
- Blood based biological marker for Alzheimer's diseasebaseline to year three
Tau, amyloid, and neurodegenerative levels in blood samples